On the other hand, a phase III randomized controlled trial (RCT) with ravulizumab, another anti-C5 monoclonal antibody with a prolonged half-life compared to eculizumab, (NCT04369469), that involved patients with severe COVID-19 who required mechanical ventilation has been stopped after an interim analysis revealed a lack of efficacy (Covid-19 roundup, 2021). The gene discussed is C5; the disease is COVID-19.